cyrilzakka/clinical-trials huggingface dataset:
Brain-based Understanding of Individual Language Differences After Stroke

Strokes often cause a loss of communication ability, referred to as aphasia, as well as cognitive difficulties. Each stroke survivor has a unique pattern of strengths and weaknesses in communication and cognition, and a unique course of recovery. The BUILD study aims to understand the brain basis of these individual differences in stroke outcome. Participants with stroke as well as controls matched in age, educational background, race, and sex are examined using a combination of standardized and in-house tests of language and cognition to provide a detailed profile of strengths and weaknesses. Each participant will have between three and six sessions, including an MRI to measure details of the structure, function, and connections in the brain. The data are analyzed to test how patterns in the stroke lesion explain the patterns of communication and cognitive difficulties, and how patterns in the uninjured parts of the brain explain resilience and recovery from the stroke. Ultimately, we hope that BUILD will guide us toward new targets for brain stimulation treatments or other biologically based treatments that improve language and cognitive abilities after stroke.


Eligibility Criteria:
Inclusion Criteria:

Stroke Survivors:

* Age \>=18
* Stroke in left hemisphere of brain with or without aphasia, or stroke elsewhere causing aphasia
* Learned English at 8 years or younger

Controls:

* Age \>=18
* No history of brain injury resulting from stroke, trauma, infection (i.e. encephalitis), or tumor
* Learned English at 8 years or younger

Exclusion Criteria:

* History of other brain conditions that could impact interpretation of results (such as multiple sclerosis, premorbid dementia)
* Severe psychiatric condition that would interfere with participation in the study
* History of a learning disability that could impact interpretation of results

Additional Exclusion Criteria for MRIs:

* Pacemaker or magnetic metal in the body that is not MRI compatible
* Pregnancy
* Claustrophobia
IS ElastomEtry Useful in Muscle Lesion evaluaTion-REPROducibility Study

Our objective is to evaluate the inter and intra observer reproducibility of the measure of elasticity using Acoustic Radiation Force Impulse (ARFI) ultrasonography of mucles of patients with and without hamstring injury.

76 patients will be evaluated cross sectionally twice by two ultrasonographists.

Muscle trauma mainly results from sporting activities and accounts for 10 to 55% of sports injuries.

Information on ARFI muscle trauma management is scarce. The present study sought to assess the initial ARFI characteristics of muscle in sports people with and without injury.

Our objective here is to evaluate the inter and intra observer reproducibility of the measure of elasticity using Acoustic Radiation Force Impulse (ARFI) ultrasonography of muscles of patients with and without hamstring injury.

76 patients will be evaluated cross sectionally twice by two ultrasonographists(and then we will evaluate the evolution after 3 months for patient with injury according to the ARFI results).

Eligibility Criteria:
Inclusion Criteria:

* Patients justifying an ultrasound evaluation for suspicion of muscle injury

Exclusion Criteria:

* Inflammatory muscle disease
Clindamycin in Prosthetic Joint Infections Caused by Staphylococcus (CISTA)

The alternatives to the combination of Fluoroquinolone and Rifampicin in prosthetic joint infections (PJI) caused by staphylococcus are currently unclear. Clindamycin is prescribed as dual therapy in this indication, and provides many advantages. We conducted a multicenter retrospective observational study evaluating the efficacy and safety of Clindamycin in prosthetic joint infections due to staphylococcus between January 2013 and December 2019.


Eligibility Criteria:
Inclusion Criteria:

* Patients with PJI defined according to the IDSA.
* Infection must be mono-microbial or multi-microbial with Staphylococcus spp sensitive to Clindamycin.
* Infection may be acute or chronic, nosocomial or community-acquired.
* Patient having received a curative treatment with Clindamycin.

Exclusion Criteria:

* Patients with osteitis, osteomyelitis, septic arthritis in native joints, diabetic foot infections, spondylodiscitis, infections in external fixator, surgical site infections following neurosurgical management, bedsores, skin and soft tissue infections.
* Patients with mono-microbial infections other than Staphylococcus, multi-microbial infections including other bacteria than Staphylococcus, suspected Osteoarticular Infection without microbial identification.
* Patients with clindamycin-resistant Staphylococcal PJI, constitutive MLSb phenotype.
* Patients having received suspensive treatment with Clindamycin.
* Patients treated with Clindamycin as last line of treatment for a duration of less than 14 days.
* Patients refusing to participate
* Patients under legal protection (guardianship, curatorship, ..)
Timed Interval Measurement of Eotaxin in Stroke Study

Stroke is caused by sudden changes in blood flow in the brain. This can be fatal or can result in permanent disability. A fast diagnosis is essential to initiate effective interventions and optimize benefits to patients. There are other diseases that can look like a stroke and these are called "stroke mimics". The quicker that stroke mimics can be ruled out the faster a stroke can be diagnosed and treatment can be given. The investigators may be able to use chemicals in the blood to rapidly confirm that a person has had a stroke. One such chemical is called eotaxin. Eotaxin has been found to be changed in sufferers of a stroke but not in those with stroke mimics. However, more research is needed to confirm the usefulness of eotaxin. This feasibility study aims to provide the foundations to allow a large scale trial of this test. The study aims to recruit participants that have had a stroke or a stroke mimic from the Acute Stroke Unit and Stroke clinic at the Royal Devon and Exeter Hospital. Up to 6 blood samples will be taken from each participant at different times over one week. Eotaxin will be measured in these samples and in participant's leftover samples taken for clinical care. This is needed because the investigators know that the amount of eotaxin changes in the blood after a stroke but we do not know how quickly this change happens and for how long the change occurs. The study will also allow the investigators to understand how many participants will be needed for a large scale trial and the challenges that may be faced in recruiting participants.


Eligibility Criteria:
Inclusion Criteria:

* Presenting with focal neurological symptoms suggestive of stroke
* Aged over 18 years

Exclusion Criteria:

* Presenting later than 12 hours after symptom onset
* Under 18 years of age
* History of cardiovascular disease (Healthy Controls)
* History of neurological disease (Healthy Controls)
* History of stroke mimics (Healthy Controls)
Clinical Pharmacology of MDA [3,4-methylenedioxyamphetamine]

The purpose of this study is to investigate the pharmacological and cognitive effects of MDA in healthy humans.


Eligibility Criteria:
Inclusion Criteria:

* Healthy males and females age 18-50
* Fluent English speaker
* Willing and able to give written consent

Exclusion Criteria:

* Body mass index \> 30 or \< 18
* Pregnancy or lactation

FOR MORE DETAILS CONTACT THE RESEARCH CLINIC.
General Practitioner's Place in the Treatment of Fracture Osteoporosis in the Elderly

Osteoporosis is a major public health problem. Its screening and its treatment remain largely insufficient while therapies have demonstrated their effectiveness. In the event of a severe fracture, the update of the 2016/2017 recommendations, prepared by the Research and Information Group on Osteoporosis and the French Rheumatology Society, concerning osteoporosis recommends a specific treatment with bisphosphonates as first-line treatment, without bone densitometry, regardless of age. The frequency of prescribing anti-osteoporotic treatment as an outpatient after a fracture of the upper extremity of the femur is very low (2% to 21% according to the studies). The main factors associated with non-prescription found are co-morbidities (charlson score\> 6), dementia, obesity (BMI\> 30), chronic alcoholism, male sex, polypharmacy\> 4, age. Conversely, the factors associated with prescribing are recurrent falls (\> 2 / year), a history of osteoporotic fracture, an Iso Resource Group\> 3, female sex, and corticosteroid therapy.

1. / The collection of patients' characteristics upon admission will be based on the computerized patient file and the paper file: socio-demographic data, co-morbidities, functional status, entry / exit treatments, place of residence, source, balance sheet hospital.
2. / Determination with the treating doctor or the pharmacist of the prescriptions of the anti-osteoporotic treatments at 6 months of the hospital care.
3. / Research factors associated with the prescription (or non-prescription) of anti-osteoporotic treatments.

Eligibility Criteria:
Inclusion Criteria:

* Subjects aged 75 or over (hospitalization criteria in the pathway), admitted to the ortho-geriatric ward of the Saint Malo Hospital Center, treated for a fracture of the upper extremity of the femur.

Exclusion Criteria:

* High-energy fracture, pathological fractures (infection, tumor), persons of legal age subject to legal protection (safeguard of justice, guardianship, guardianship), persons deprived of their liberty.
Emerging Biomarkers in Hypertension

First of all to evaluate the relationship between non-conventional biomarkers and essential hypertension; then to evaluate the effects of various anti-hypertensive drugs on blood pressure control and non-conventional biomarkers in naive hypertensive patients


Eligibility Criteria:
Inclusion Criteria:

* essential hypertension
* naive to treatment
* \< 65 years

Exclusion Criteria:

* secondary hypertension
* previous cardiovascular events
Proprioceptive Training vs. Hip Abductor With External Rotator Strengthening in Patients With Patellofemoral Pain

Patellofemoral pain syndrome (PFPS) is a common musculoskeletal disorder characterized by an insidious onset of pain in the knee's anterior /retro-patellar / peripatellar region. Even though various rehabilitation approaches, including hip strengthening and proprioceptive training, are being considered for managing PFPS, the most appropriate treatment from these two is still unclear. Therefore, this study aimed to compare the program consisting of hip abductors and external rotators strengthening exercises vs. the program consisting of proprioceptive training of the knee to identify the most effective rehabilitation approach for patients suffering from PFPS.


Eligibility Criteria:
Inclusion Criteria:

* Age 18-35 years
* Patients diagnosed recently by an orthopedic surgeon for Patello-femoral pain syndrome
* experiencing anterior/retro patellar knee pain during activities,
* insidious onset of symptoms not linked to trauma,
* pain persisting for no less than four weeks,
* pain on palpation of the patellar facets,
* pain when stepping down from a 25-cm step or during a double-legged squat.

Exclusion Criteria:

* Patients with recent lower limb fractures or dislocations,
* knee/hip joint surgery,
* signs, symptoms, or radiological findings of intra-articular pathology such as effusion, ligamentous or meniscal involvement,
* those with indications of patellar apprehension,
* referred pain from the hip, back, or sacroiliac joint,
* acute knee strain or sprain,
* on medication such as NSAIDs or corticosteroids,
* degenerative and infectious arthritis
Improving Cardio-metabolic and Mental Health in Women With Gestational Diabetes Mellitus and Their Offspring

MySweetHeart Trial is a randomized controlled trial to test the effect of a multidimensional interdisciplinary lifestyle and psychosocial intervention to improve the cardio-metabolic and mental health of women with GDM and their offspring.

Primary objective of MySweetHeart Trial:

To test the effect of a multidimensional interdisciplinary lifestyle and psychosocial intervention in women with GDM to improve 1) their metabolic health (decrease in maternal weight between study inclusion after GDM diagnosis and at 1 yr postpartum) and 2) their mental health (decrease in maternal symptoms of depression during the same time period).

Secondary objective of MySweetHeart Trial:

To test the effect of a multidimensional interdisciplinary lifestyle and psychosocial intervention to improve other cardio-metabolic and mental health markers in women with GDM and their offspring.

MySweetHeart trial is linked to MySweetHeart Cohort, an observational cohort study that assesses the effect of GDM on offspring cardiovascular health early in life. The principal investigators of the cohort are Nicole Sekarski and Arnaud Chiolero (University Hospital Lausanne, Switzerland). Their primary objective is to assess the effect of GDM on the surrogate markers of cardiovascular disease (CVD) at birth (left ventricular mass index and subclinical atherosclerosis) and the secondary objective is to assess the effect of GDM on the cardiovascular structure and function during the fetal period and neonatal adverse cardiovascular risk factors.


Eligibility Criteria:
Inclusion Criteria:

* Women and their partners aged 18 yrs or older, with GDM at 24-32 weeks of gestation, and understanding French or English.

Exclusion Criteria:

* Women on strict bed-rest, with pre-existing diabetes or known severe mental disorder.
Olive Oil and Soybean 1 Oil Based Intravenous Lipid Emulsions, Liver Chemistry and Clinical Outcomes

Background: Intravenous lipid emulsions (IVLE) are an essential component of parenteral nutrition (PN). Omega-6 reducing strategies may improve outcomes, including reduced PN associated liver disease.

Objective: The primary objective was to compare serum alkaline phosphatase (ALP), among surgical and medical patients provided with either Intralipid or Clinoleic lipid emulsions.

Design: In this quasi-experimental study the medical records of surgical and medical adult patients were reviewed from 3 Canadian hospitals that received PN with either soybean oil (Intralipid) or predominantly olive oil (Clinoleic) based lipid emulsions for at least 7 consecutive days.

A few small studies have shown that a predominantly olive oil based IVLE is well tolerated and safe, however the clinical relevance of this IVLE is uncertain as no clear benefit in outcomes has been observed in small randomized clinical trials. Given the limited data available for the adult population reporting on the experience with olive oil based IVLE, we designed a quasi-experimental study to review our experience with Clinoleic compared to Intralipid. The primary objective was to compare the impact of Intralipid and Clinoleic IVLE on serum alkaline phosphatase (ALP), pre-PN to after one week of PN (i.e. between day 8 to 16 post-PN initiation), while controlling for the ordered lipid dosing. Secondary objectives were to assess if there were differences between the IVLEs on the remaining liver function tests, lipid dosing, incidence of infectious complications, length of stay in hospital and 30- day mortality.

This retrospective quasi-experimental chart review was conducted in 3 tertiary care hospitals in Calgary, AB between July 01, 2012 to June 30, 2013 and July 01, 2014 to June 30, 2015. Standard soybean oil-based therapy, Intralipid was the only available IVLE in Calgary, AB until July 2013, at which time predominantly olive oil Clinoleic was approved as an alternative in the hospital formulary, accounting for the dates chosen for the study. Ethics approval from the Conjoint Health Research and Ethics Board at the University of Calgary was obtained prior to the initiation of the study.

Eligibility Criteria:
Inclusion Criteria:

* admitted to hospital who received PN with Intralipid or Clinoleic IVLEs for at least 7 consecutive days.

Exclusion Criteria:

* baseline liver disease
* home PN prior to admission
* ALP and total bilirubin (TB) not available within 3 days prior to PN start as well as between days 8 to 16 post PN start
* receipt of Diprivan 1%® (Propofol 116 - AstraZeneca Canada Inc., Mississauga, Canada) during PN support period
* enteral nutrition providing greater than 600 Kcal daily for longer than half of time period on PN
* oral intake of greater than 50% of hospital meal tray contents for longer than half of the PN support time period
Extracorporeal Life Support and Modification of Hemostasis

To evaluate change in coagulation tests during a 48-h period after initiation VV-ECMO and VA-ECMO.

(ECMO= Extra Corporeal Membrane Oxygenator) Assessment of bleeding during Veno-Venous Extracoporeal Membrane Oxygenator (VV-ECMO) and Veno-Arterial Extracoporeal Membrane Oxygenator (VA-ECMO).

This is a multi-center, prospective, pilot cohort study, performed in the Intensive Care Units (ICUs) of the Ghent University Hospital, CHU Liège, University Hospital Brussels, and University Hospital Munster.

Each group will contain 20 subjects; in total there will be 40 subjects 2 groups of 20 patients GROUP 1: VV-ECMO n = 20 GROUP 2: VA-ECMO n = 20

* Demographics: age, sex, comorbidities, medication, reason for ECMO therapy
* Simplified Acute Physiology Score (SAPS) 3 at time of ICU admission.
* Components of the Sequential Organ Failure Assessment score daily (based on worst value of each component of the score)
* ECMO characteristics (place of cannulation, type of cannulas, oxygenator, bloodflow, gasflow and pressure registrations)
* Incidence and severity of bleeding, scored according to the GUSTO and BARC scores
* Coagulation profile: At inclusion (before heparine infusion is started), 2h after start of therapy, 24h, and 48h, and at specific moments of clinical suspicion of profound altered hemostasis. We defined a coagulation profile as a set of tests that includes

  * prothrombin time (PT), international normalized ratio (INR)
  * activated partial thromboplastin time (aPTT) and heparin ratio
  * the fibrinogen level
  * platelets
  * ACT (iACT®, ...)
  * D-dimer
  * ROTEM (extem, intem, heptem) or TEG (Utrecht)
  * AT III
  * anti Xa
* Temperature daily (H/L) (core)
* Patient characteristics that may influence coagulation or the results of coagulation tests: body weight, Body Mass Index, drugs, C-reactive protein (as a marker for inflammation), Hemoglobin level, LDH, unconjugated bilirubin, (or haptoglobine or plasma free haemoglobin, if tested)
* Heparin dose

Eligibility Criteria:
Inclusion Criteria:

* GROUP 1: patients who will be initiated on VV-ECMO within a 12-h period
* GROUP 2: patients who will be initiated on VA-ECMO within a 12-h period
* ≥ 18 years
* Signed Informed Consent, signed by subject or authorized representative

Exclusion criteria:

Expected survival \<48-h Known coagulopathy Pregnancy
Whole Body MRI Imaging in Multiple Myeloma at 3 Tesla MRI : Added Value of Diffusion Weighted Imaging

Whole body MRI with diffusion weighted imaging is a useful imaging tool

* staging and diagnosis
* therapy monitoring All patients will be scanned before and during treatment. The findings on diffusion weighted imaging will be correlated to the golden standard (computer tomography and MRI (T1 and STIR)).


Eligibility Criteria:
Inclusion Criteria:

* Patients with clinical and laboratory findings, highly suggestive for multiple myeloma.

Exclusion Criteria:

* All patients who are not allowed to be scanned on MRI (Pacemaker, implants ed.)
Study of Methylnaltrexone (MNTX) for the Relief of Constipation

To determine the efficacy of subcutaneous MNTX to relieve opioid-induced constipation in patients with advanced medical illness.

This is a multi-center, double-blind, randomized parallel group study conducted in patients with advanced medical illness and opioid-induced constipation. Eligible patients are randomly assigned to receive SC doses of either MNTX, dose 1 or placebo every other day for 2 weeks. At Day 8, eligible patients, if allowed, could be escalated to a a higher dose of MNTX.

Eligibility Criteria:
Inclusion Criteria:

* 18 years of age and older
* Negative pregnancy test (serum or urine) at screening for all women of childbearing potential
* Advanced Medical Illness (i.e., terminal illness, such as incurable cancer or end of stage AIDS) with life expectancy of ≥ 1 month
* patient must sign ICF

Exclusion Criteria:

* Women who are pregnant and/or nursing
* Previous treatment with MNTX
* Participation in any other studies involving investigational products within 30 days prior to screening
Cerebellar iTBS in Patients With Disorders of Consciousness

Previous studies showed the excitatory effect of cerebellar transcranial magnetic stimulation(TMS) on motor cortex.Investigator evaluate the effects of bilateral cerebellar TMS on Coma Recovery Scale-Revised (CRS-R) scores in patients with disorders of consciousness(DOC) in a randomized, double-blinded, sham-controlled, crossover experimental design.

Patients with disorders of consciousness(DOC) resulting from severe brain injury greatly burden caregivers, health care facilities, and society. However, there is no definitively effective treatment for patients with DOC.

Previous studies showed the excitatory effect of cerebellar transcranial magnetic stimulation(TMS) on motor cortex through the dentato-rubro-thalamic tract. Investigators aim to validate the effect of 5 consecutive sessions of intermittent theta-burst stimulation(iTBS) of bilateral cerebellar on level of consciousness of patients in vegetative state(VS)/unresponsive awakening state(UWS)or minimally conscious (MCS) state in a randomized, double-blinded, sham-controlled, crossover study.

TMS is a non-invasive and safe neural regulatory approach that is widely used in depression, schizophrenia, stroke, and Parkinson's disease.

Eligibility Criteria:
Inclusion Criteria:

1. VS/UWS or MCS according to diagnostic criteria
2. Age ≥18 years
3. Written informed consent obtained

Exclusion Criteria:

1. Patients in coma
2. Brain injury \<1week
3. Presence of metallic hardware in close contact to the discharging coil（such as cochlear implants, or an Internal Pulse Generator or medication pumps）
4. Patients with high risks according to standard questionnaire to screen transcranial magnetic stimulation(TMS) candidates
A Study of Tarceva (Erlotinib) and Avastin (Bevacizumab) in Patients With Advanced or Metastatic Liver Cancer.

This single arm study evaluated the efficacy and safety of a combination of Tarceva and Avastin in patients with advanced or metastatic liver cancer. Patients were treated with Tarceva 150 mg po daily plus Avastin 5 mg/kg intravenous (iv) every 2 weeks. The anticipated time on study treatment was until disease progression, and the target sample size was \<100 individuals.


Eligibility Criteria:
Inclusion Criteria:

* adult patients, ≥ 18 years of age;
* advanced or metastatic liver cancer;
* ≥ 1 measurable lesion, not previously treated with local therapy within 4 weeks of enrollment.

Exclusion Criteria:

* prior or concomitant systemic anti-cancer treatment for advanced disease;
* patients at high risk of variceal bleeding;
* clinically significant cardiovascular disease;
* major surgery, open biopsy, or significant traumatic injury within 4 weeks of study start.
Phrenic Nerve Injury During Pulmonary Vein Isolation With the Second-generation Cryoballoon.

To determine the most frequent complication associated with cryoballoon PVI. The main hypothesis is to explore the incidence of phrenic nerve palsy.


Eligibility Criteria:
Inclusion Criteria:

* age 18 years or older
* Cryoballoon PVI
* Periprocedural phrenic lesion

Exclusion Criteria:

- Non